Advisory review committees of Japan’s Ministry of Health, Labour and Welfare (MHLW) have decided for the second time in the past month not to grant an emergency approval to Shionogi & Co. Ltd.’s oral COVID-19 drug Xocova (ensitrelvir; S-217622), casting further questions around the 3CL protease inhibitor's path to market.
Local interest in the once-daily drug has been high and also heightened by a recent spike in confirmed coronavirus cases...







